Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 4Recurrence 3Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 155Rituximab 148Etoposide 84fludarabine phosphate 73Peripheral Blood Stem Cell Transplantation 68Mycophenolic Acid 63Busulfan 62Filgrastim 59Melphalan 58Tacrolimus 54Whole-Body Irradiation 51Cytarabine 46fludarabine 45Radiotherapy 43Methotrexate 41Granulocyte Colony-Stimulating Factor 41Cyclosporine 41Vincristine 35Antilymphocyte Serum 35Carmustine 33Doxorubicin 29Prednisone 26Thiotepa 25Bendamustine Hydrochloride 24Methylprednisolone 22Ifosfamide 22Dexamethasone 22thymoglobulin 21sargramostim 20plerixafor 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Non-Hodgkin × Automobiles × Clear all
NCT04089215 2023-11-24

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 2 Unknown
82 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04718883 2023-11-24

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 2 Active not recruiting
59 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡